Dupilumab (Dupixent)

Abstract


 Clinical evidence suggests that Dupixent should be reimbursed to treat patients aged 12 years and older with severe asthma and with a type 2 or eosinophilic phenotype or oral corticosteroid–dependent asthma.
 Economic evidence suggests that a 93% price reduction is needed to ensure Dupixent is cost-effective at a $50,000 per quality-adjusted life-year threshold relative to standard of care alone.
 Cost-effectiveness versus other biologics is unknown.
 CADTH was unable to estimate the budget impact due to a high degree of uncertainty.

Prescribing Patterns of Dupilumab for Atopic Dermatitis in Adults: Retrospective, Observational Cohort Study

“…Compared with the aforementioned systemic immunomodulating agents, dupilumab may be more effective as a long-term maintenance therapy and has the advantage of an overall improved side-effect profile, with no required drug-specific laboratory monitoring [11]. However, access to this immunomodulator may be limited by its novelty and cost (depending upon the dose, up to US $59,000/year for patients without insurance) [13].The disease burden of AD disproportionately affects non-Hispanic Black patients; the source of this disparity is multifactorial. Although the specific gene-environment interactions in the pathophysiology of AD are unknown, many factors-such as differences in environmental pollution, contact with tobacco smoke, hygiene practices, access to health care, diet, and exposure to disease-likely play a role [4,14,15].…”